MedTrace Logo

Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1)

NCT06193174 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2026-01-22

No results posted yet for this study

Summary

The purpose of this study is to determine how safe and how well-tolerated the experimental study drug, C134 is when re-administered into the brain where the tumor is located.

Conditions

  • Recurrent Malignant Glioma
  • Glioblastoma Multiforme of Brain
  • Gliosarcoma of Brain
  • Anaplastic Astrocytoma of Brain

Interventions

DRUG

C134 Re-Administration

Administration of a second dose of C134 to participants that have completed the study Trial of C134 in Patients With Recurrent GBM (C134-HSV-1).

Sponsors & Collaborators

  • University of Alabama at Birmingham

    lead OTHER

Principal Investigators

  • James Markert, MD · The University of Alabama at Birmingham

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-21
Primary Completion
2025-03-07
Completion
2025-03-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06193174 on ClinicalTrials.gov